Summary: In current investigation, combinatorial delivery of anti-neoplastic drug and siRNA was achieved to enhance the effectiveness of cisplatin in A549 lung cancer cell line. The formulated co-loaded nanocarriers imparted stability to the siRNA in presence of serum and delivered the payload efficiently inside the cells as evident from the transfection efficiency study besides showing improvement in loading efficiency of the drug as well as cytotoxicity as compared to the free drug. Delivery of ABCC3 siRNA complexed HNCs for ABCC3 protein exerted knock-down of expression leading to sensitization of cancer cells to cisplatin. A significant reduction in tumor growth along with superior pharmacokinetics profile was observed with the formulation. Thus, this approach has potential for effective management of cancer using genomic approach with improved therapeutic index and could be able to reduce dose dependent toxicity of the cisplatin.
The Editorial Board of DDTR selected this article as the best paper of this issue. This article will be free to access until November 24, 2021.
